Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1984 1
1985 3
1986 1
1987 1
1989 1
1995 1
1997 3
1998 3
1999 1
2000 1
2001 3
2002 1
2003 1
2005 1
2006 3
2008 1
2009 3
2010 3
2011 3
2012 3
2013 3
2014 3
2015 6
2016 1
2018 1
2019 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
[Gluten migraine].
Kopishinskaya SV, Gustov AV. Kopishinskaya SV, et al. Among authors: gustov av. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8):13-17. doi: 10.17116/jnevro20151158113-17. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID: 26356609 Russian.
[Genetic aspects of migraine].
Kopishinskaya SV, Gustov AV. Kopishinskaya SV, et al. Among authors: gustov av. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(7):124-129. doi: 10.17116/jnevro201511571124-129. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID: 26356526 Review. Russian.
[Ophthalmic manifestations of Huntington's disease].
Svetozarskiy SN, Kopishinskaya SV, Gustov AV, Radyuk MA, Antonova VA, Smetankin IG, Svetozarskiy SN, Kopishinskaya SV, Gustov AV, Radyuk MA, Antonova VA, Smetankin IG. Svetozarskiy SN, et al. Among authors: gustov av. Vestn Oftalmol. 2015 Sep-Oct;131(5):82-86. doi: 10.17116/oftalma2015131582-86. Vestn Oftalmol. 2015. PMID: 26845877 Review. Russian.
[Huntington's disease].
Kopshynskaya SV, Antonova VA, Gustov AV. Kopshynskaya SV, et al. Among authors: gustov av. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(1):74-9. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID: 24678542 Review. Russian. No abstract available.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
[Polyneuropathy of thin fibers].
Kopishinskaya SV, Lauriya D, Gustov AV, Radyuk MA. Kopishinskaya SV, et al. Among authors: gustov av. Klin Med (Mosk). 2015;93(1):18-22. Klin Med (Mosk). 2015. PMID: 26031144 Review. Russian.
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. Reilmann R, et al. Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15. Lancet Neurol. 2019. PMID: 30563778 Clinical Trial.
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Cerebrovasc Dis. 2009. PMID: 19372653 Free article. Clinical Trial.
54 results